Canopy GrowthHAM:11L +0.95%60 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates HAM:11L with a GF Score™ of 60/100 and a GF Value™ of €0.65 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 684 Drug Manufacturers companies, Canopy Growth ranks worse than 146198.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Canopy Growth's
Operating Income
for the
three
months ended in Mar. 2026 was €-17.3 Mil. Canopy Growth's Interest Expense for the
three
months ended in Mar. 2026 was €-7.8 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Canopy Growth's Interest Coverage or its related term are showing as below:
HAM:11L's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.765 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Canopy Growth Interest Coverage Related Terms
Canopy Growth Interest Coverage Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HAM:11L vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Canopy Growth did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Canopy Growth (HAM:11L) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Canopy Growth and its competitors. According to the industry distribution chart, Canopy Growth ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is Canopy Growth's Interest Coverage too high?
Canopy Growth's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Canopy Growth ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Canopy Growth has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #999999 out of 684 companies for Interest Coverage. This places Canopy Growth in the lower half of its industry. The industry median Interest Coverage is 12.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €0.83 — trading 27.4% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Canopy Growth's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.83 is trading 27.4% above its estimated GF Value™ of €0.65.
GuruFocus considers Canopy Growth to be Modestly Overvalued.
Key valuation signals for HAM:11L:
Interest Coverage: 0 (At Loss)
GF Value™: €0.65 vs. price of €0.83 (27.4% above fair value)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
60GF Score
Get the complete analysis for HAM:11L
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
